Analyzing Cost of Revenue: AstraZeneca PLC and Alkermes plc

Analyzing Cost of Revenue: AstraZeneca PLC vs. Alkermes plc

In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. Over the past decade, AstraZeneca PLC and Alkermes plc have shown contrasting trends in their cost of revenue. From 2014 to 2023, AstraZeneca's cost of revenue surged by approximately 38%, peaking in 2021 with a remarkable 124% increase compared to 2016. This reflects AstraZeneca's aggressive expansion and investment in new drug development. In contrast, Alkermes plc experienced a more volatile trajectory, with a notable dip in 2022, where costs plummeted by 62% from their 2019 peak. This fluctuation may indicate strategic shifts or operational challenges. As we look to the future, these trends offer valuable insights into each company's strategic priorities and market positioning.